50% OFF

Cash Flow Health Analysis Report for Shuangjie Electric (SZ300444)

#cash_flow_analysis #financial_health #negative_cash_flow #shuangjie_electric #stock_analysis #risk_warning #industrial_machinery #working_capital #valuation_disconnect
A-Share
January 20, 2026

Unlock More Features

Login to access AI-powered analysis, deep research reports and more advanced features

About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.

Related Stocks

300444
--
300444
--

Now let me prepare the complete cash flow health analysis report for you:


Cash Flow Health Analysis Report for Shuangjie Electric (SZ300444)
1. Company Basic Information

Shuangjie Electric (Beijing Shuangjie Electric Co., Ltd.) is a listed company focusing on the industrial machinery sector. Its stock price has performed strongly since 2026, rising by over 121% in the past year, with a current market capitalization of approximately USD 11.84 billion[0]. However, the strong stock performance shows a clear divergence from its cash flow fundamentals.


2. Core Cash Flow Indicator Analysis
2.1 Operating Cash Flow (OCF) Trend
Fiscal Year Operating Cash Flow (CNY) YoY Change
2020 +158 million -
2021 -272 million -272.5%
2022 -210 million +22.9%
2023 +206 million +198.1%
2024 -645 million -413.2%

Key Findings:

  • Negative operating cash flow in 3 out of 5 years (60%)
  • Highly volatile operating cash flow
    , which deteriorated sharply in 2024, turning from a surplus to a deficit of 645 million yuan
  • Operating cash flow shows a “rollercoaster” trend, lacking stable cash generation capacity
2.2 Free Cash Flow (FCF) Status
Fiscal Year Free Cash Flow (CNY)
2020 -76 million
2021 -645 million
2022 -304 million
2023 -238 million
2024 -872 million

Key Findings:

  • Negative free cash flow for 5 consecutive years
    , never turning positive
  • The free cash flow gap widened to 872 million yuan in 2024, a record high
  • Capital expenditure (Capex) accounts for a relatively high proportion, with the 2024 Capex/revenue ratio reaching 6.5%[0]

3. Comprehensive Assessment of Cash Flow Health
3.1 Key Financial Ratios
Indicator 2024 Data Industry Reference Evaluation
Operating Cash Flow/Revenue
Negative
>10% ❌ Severely Abnormal
Free Cash Flow/Revenue
Negative
>5% ❌ Severely Abnormal
EV/Operating Cash Flow -10.39x 8-15x ❌ Negative Value Abnormal
P/OCF Ratio -8.59x 10-20x ❌ Negative Value Abnormal
Income Quality Index -7.97 >1.0 ❌ Severely Deteriorated
Current Ratio 1.24 1.5-2.0 ⚠️ Below Average
Cash Ratio 0.73 >0.5 ✅ Acceptable
3.2 DuPont Analysis Perspective
  • Debt-to-Equity Ratio
    : Rose to 1.07x in 2024 (0.49x in 2023), indicating a significant increase in leverage[0]
  • ROE (Return on Equity)
    : Only 4.98% in 2024, a relatively low level
  • Interest Coverage Ratio
    : 2.60x, indicating weak debt-servicing capability

4. Diagnosis of Structural Cash Flow Issues
4.1 Reasons for Deteriorating Operating Quality
  1. Deteriorating Accounts Receivable Turnover

    • Accounts Receivable Turnover Days: Reached
      235.8 days
      in 2024 (169.3 days in 2023)
    • The collection period has been significantly extended, occupying a large amount of working capital
  2. Slowing Inventory Turnover

    • Inventory Turnover Days:
      216 days
      in 2024 (137.2 days in 2023)
    • Severe inventory backlog, with cash flow tied up in inventory
  3. Extended Accounts Payable Period

    • Accounts Payable Turnover Days:
      268.6 days
      in 2024 (140.5 days in 2023)
    • While extending payment terms can relieve cash flow pressure in the short term, it is unsustainable
4.2 Cash Flow Gap Analysis
Operating Cash Flow Gap = Operating Revenue × Operating Cash Flow Ratio
                ≈ 3.47 billion yuan × (negative value)
                
Free cash flow remaining negative indicates:
- The company cannot generate sufficient cash from its core operations
- Capital expenditure intensity is high, with expansion consuming a large amount of cash
- Relies on external financing to maintain operations

5. Divergence Analysis with Stock Price Performance
Indicator Data Contradiction
Stock Price Gain in Past Year +121.52% Contradicts fundamentals
P/E (Price-to-Earnings Ratio) 68.48x Built on fragile earnings
Operating Cash Flow -645 million yuan Cannot support valuation

Risk Warning
: The stock price increase may be driven by market sentiment, theme speculation, or liquidity, rather than supported by fundamental improvements.


6. Conclusion and Investment Recommendations
✅ Cash Flow Health Rating:
Unhealthy
🔴 Core Issues
  1. Sustained negative operating cash flow
    – Lack of cash generation capacity from core businesses
  2. Negative free cash flow for 5 consecutive years
    – The company has been consuming cash rather than creating value
  3. Deteriorating working capital management
    – Significant slowdown in accounts receivable and inventory turnover
  4. Rapidly rising leverage
    – Debt-to-equity ratio doubled in one year, increasing financial risk
  5. Divergence between cash flow and valuation
    – High valuation is built on fragile fundamentals
📊 Cash Flow Health Scorecard
Dimension Score Explanation
Operating Cash Flow Stability 2/10 Frequently negative, highly volatile
Free Cash Flow Generation 0/10 Negative for 5 consecutive years
Working Capital Efficiency 3/10 Turnover days deteriorated significantly
Debt-Servicing Capability 5/10 Current ratio >1 but below average
Earnings Quality 2/10 Severe divergence between cash flow and profits
Composite Score
2.4/10
Unhealthy
⚠️ Risk Warnings
  • If operating cash flow fails to improve, the company may face a
    liquidity crisis
  • High leverage combined with negative cash flow,
    debt default risk
    deserves attention
  • The current stock price gain lacks fundamental support, with high
    valuation reversion risk

Data Source
: [0] Jinling AI Financial Database


For more in-depth investment research analysis, you may consider enabling the

Deep Research Mode
to obtain more detailed A-share financial data, company comparative analysis, and industry research.

Previous
No previous article
Next
No next article
Related Reading Recommendations
No recommended articles
Ask based on this news for deep analysis...
Alpha Deep Research
Auto Accept Plan

Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.